Locus Biosciences

Locus Biosciences Announces $23.9 Million in Funding from BARDA to Support First Phase 2 Trial of CRISPR-engineered Bacteriophage Therapy

Retrieved on: 
Tuesday, January 23, 2024
Locus Biosciences, Development, Escherichia coli, World Health Organization, Patient, MDR, Part, Genetically modified bacteria, CRISPR, Partnership, UTI, Administration, Infection, Public, Recurrence, Food, Part Two, Urinary tract infection, Human services, Marketing, Clinical trial, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases, today announced the release of $23.9 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to continue the development of Locus’ CRISPR-enhanced bacteriophage therapy, LBP-EC01, for treating urinary tract infections (UTIs) caused by drug-resistant Escherichia coli (E. coli) based on positive results from a Phase 2a clinical trial.

Key Points: 
  • Approximately 80% of these are caused by E. coli, often including difficult-to-treat strains that are resistant to commonly used antibiotics.
  • The funding will be used to advance LBP-EC01 into the blinded, placebo-controlled, Part 2 of the ELIMINATE Phase 2 trial.
  • In 2020, Locus and BARDA announced an agreement to co-fund development of LBP-EC01.
  • The award announced today brings the amount released under the contract to $48.9 million.

BioAesthetics Welcomes Joseph Nixon to its Board of Directors

Retrieved on: 
Wednesday, August 23, 2023
Research, Other Health, Oncology, Consumer, Medical Devices, Surgery, Clinical Trials, Science, Biotechnology, Women, Stem Cells, Health, Other Science, Cleveland Clinic, Locus Biosciences, Quality of life, Case Western Reserve University, Locus, Corporation, Mastectomy, Novartis, Patient, Harvard Business School, Ideation, North Carolina Biotechnology Center, Burns, Cleveland, POP, Breast cancer, Pharmaceutical industry, Nursing, Alkermes, Biology

BioAesthetics Corporation announced today the appointment of Mr. Joseph Nixon to its Board of Directors.

Key Points: 
  • BioAesthetics Corporation announced today the appointment of Mr. Joseph Nixon to its Board of Directors.
  • Mr. Nixon brings over 25 years of life sciences investing and operating experience to BioAesthetics.
  • Nixon brings decades of experiences to BioAesthetics’ Board.
  • “I am excited and honored to join BioAesthetics as a Director,” said Mr. Nixon.

Locus Robotics Breaks Ground for New Global Headquarters, Laying Foundation for Innovation and Growth

Retrieved on: 
Wednesday, July 26, 2023
AMR, Locus Biosciences, Locus, Robotics, Engineering, Vels Institute of Science, Technology & Advanced Studies, Growth, AI, Automation, Warehouse

WILMINGTON, Mass., July 26, 2023 /PRNewswire/ -- Locus Robotics, a global leader in autonomous mobile robots (AMRs) for warehouse automation, today broke ground for its new global headquarters in Wilmington, Massachusetts. The expansion stands as a reflection of the company's remarkable growth and its unwavering commitment to future innovation in the rapidly advancing field of warehouse automation.

Key Points: 
  • The expansion stands as a reflection of the company's remarkable growth and its unwavering commitment to future innovation in the rapidly advancing field of warehouse automation.
  • "We're thrilled to break ground on our new headquarters in Wilmington," said Rick Faulk, CEO of Locus Robotics.
  • The nearly 200,000 square foot/18,580 square meter facility in the Boston area will serve as the hub for Locus Robotics' expanding global operations and will house Locus's dynamic team of engineering, manufacturing, and operations professionals dedicated to driving innovation in robotics warehouse automation.
  • The groundbreaking of the new headquarters lays a solid foundation for the company's continuous growth and future innovations, affirming Locus Robotics' position as a global leader in warehouse automation.

Locus Robotics Breaks Ground for New Global Headquarters, Laying Foundation for Innovation and Growth

Retrieved on: 
Wednesday, July 26, 2023
AMR, Locus Biosciences, Locus, Robotics, Engineering, Vels Institute of Science, Technology & Advanced Studies, Growth, AI, Automation, Warehouse

WILMINGTON, Mass., July 26, 2023 /PRNewswire/ -- Locus Robotics, a global leader in autonomous mobile robots (AMRs) for warehouse automation, today broke ground for its new global headquarters in Wilmington, Massachusetts. The expansion stands as a reflection of the company's remarkable growth and its unwavering commitment to future innovation in the rapidly advancing field of warehouse automation.

Key Points: 
  • The expansion stands as a reflection of the company's remarkable growth and its unwavering commitment to future innovation in the rapidly advancing field of warehouse automation.
  • "We're thrilled to break ground on our new headquarters in Wilmington," said Rick Faulk, CEO of Locus Robotics.
  • The nearly 200,000 square foot/18,580 square meter facility in the Boston area will serve as the hub for Locus Robotics' expanding global operations and will house Locus's dynamic team of engineering, manufacturing, and operations professionals dedicated to driving innovation in robotics warehouse automation.
  • The groundbreaking of the new headquarters lays a solid foundation for the company's continuous growth and future innovations, affirming Locus Robotics' position as a global leader in warehouse automation.

CRISPR QC Announces Formation of Scientific Advisory Board with Rodolphe Barrangou, Gene Dantsker, Jared Carlson-Stevermer Joining; Kiana Aran to Lead

Retrieved on: 
Monday, April 10, 2023
Technology, Biotechnology, Nanotechnology, Health, Other Health, Pharmaceutical, Stem Cells, Other Science, Research, Agriculture, Genetics, Natural Resources, Science, Semiconductor, Serotiny, Locus Biosciences, The CRISPR Journal, Gene editing, United States Air Force Scientific Advisory Board, North Carolina State University, Intellia Therapeutics, Patient, Quality control, Bacteria, Therapy, Medical device, CRISPR

CRISPR QC announced the formation of its Scientific Advisory Board with the appointment of three distinguished members, Dr. Rodolphe Barrangou, Dr. Gene Dantsker, and Dr. Jared Carlson-Stevermer.

Key Points: 
  • CRISPR QC announced the formation of its Scientific Advisory Board with the appointment of three distinguished members, Dr. Rodolphe Barrangou, Dr. Gene Dantsker, and Dr. Jared Carlson-Stevermer.
  • Dr. Rodolphe Barrangou is a renowned CRISPR expert, with a long and distinguished career in the field of genome editing.
  • "I am honored to join the Scientific Advisory Board of CRISPR QC and work with a team that is committed to ensuring that the potential of CRISPR gene editing can be realized safely and efficiently.
  • “We are thrilled to welcome Dr. Barrangou, Dr. Carlson-Stevermer and Dr. Dantsker to the CRISPR QC team,” said Kiana Aran, who heads the board.

Locus Biosciences Announces First Patient Treated in the ELIMINATE Registrational Phase 2/3 Trial of LBP-EC01 for Urinary Tract Infections

Retrieved on: 
Tuesday, September 13, 2022
MDR, Bacteriophage, MPH, Inflammation, Precision medicine, Safety, Infection, Development, Assistant, FDA, Food, Office of Inspector General, U.S. Department of Health and Human Services, Virus, CRISPR, BARDA, Urinary tract infection, World, World Health Organization, Administration, Biomedical Advanced Research and Development Authority, Research Triangle Park, Partnership, Synthetic biology, HHS, Patient, Genetically modified bacteria, ASPR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Escherichia coli, History, CEO, Female, Public health, CDC, Bacteria, Artificial intelligence, WHO, RESEARCH, Research, GLOBE, Marketing, PARK, Locus Biosciences, Triangle Park (Quezon City), Biofilm, Genome, Escherichia, Recurrence, Pharmaceutical industry, Medical imaging, MBBS, EU

ELIMINATE is a registration-enabling Phase 2/3 clinical trial of lead candidate LBP-EC01, a CRISPR-enhanced bacteriophage (crPhage) precision medicine, for the treatment of urinary tract infections (UTIs) caused by Escherichia coli (E. coli) bacteria.

Key Points: 
  • ELIMINATE is a registration-enabling Phase 2/3 clinical trial of lead candidate LBP-EC01, a CRISPR-enhanced bacteriophage (crPhage) precision medicine, for the treatment of urinary tract infections (UTIs) caused by Escherichia coli (E. coli) bacteria.
  • These challenges have led to a renewed interestin exploring bacteriophage therapy for treatment of resistant and recurrent infections.
  • LBP-EC01 is a Locus crPhage therapy in development for the treatment of urinary tract infections and other infections caused by the pathogen Escherichia coli (E. coli).
  • LBP-EC01 is currently being evaluated in a registrational Phase 2/3 trial for the treatment of UTIs caused by E. coli.

CosmosID® Announces Microbiome Partnership with Locus Biosciences to Provide Long-Term Clinical Trial Support

Retrieved on: 
Tuesday, June 21, 2022
Biomedical Advanced Research and Development Authority, Therapy, Genomics, Inflammation, Genetically modified bacteria, Infection, Artificial intelligence, BARDA, Cosmetics, CEO, Locus, CRISPR, Virus, Locus Biosciences, GCP, Bacteria, Development, Partnership, Medicine, Patient, Synthetic biology, Research Triangle Park, Triangle Park (Quezon City), Medical device, Antibiotics, MD

and MORRISVILLE, N.C., June 21, 2022 /PRNewswire/ --CosmosID, a leading microbial genomics company focused on standardized, high-resolution microbiome analysis, and Locus Biosciences, Inc. ("Locus"), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases, today announced a partnership for long-term support for Locus' clinical trial initiatives.

Key Points: 
  • and MORRISVILLE, N.C., June 21, 2022 /PRNewswire/ --CosmosID, a leading microbial genomics company focused on standardized, high-resolution microbiome analysis, and Locus Biosciences, Inc. ("Locus"), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases, today announced a partnership for long-term support for Locus' clinical trial initiatives.
  • Using shotgun metagenomics, CosmosID will help Locus understand the efficacy of its products through the highest resolution microbiome analysis, starting with itsurinary tract infection clinical program.
  • "We're thrilled to partner with Locus on its groundbreaking clinical pipeline as we help the company better understand the impact of these phages on the microbiome," said Manoj Dadlani, CEO of CosmosID.
  • "The importance of maintaining a healthy microbiome is now widely accepted in medicine," said Paul Garofolo, CEO of Locus Biosciences.

Locus Biosciences Announces $35 Million Financing

Retrieved on: 
Wednesday, May 18, 2022
Biomedical Advanced Research and Development Authority, Inflammation, Locus Biosciences, Company, Urinary tract infection, Death, Escherichia coli, Viking Global Investors, Patient, Bacteria, Synthetic biology, CGMP, Medical Hypothesis, Discovery & Innovation in Ophthalmology, COVID-19, RESEARCH, Mortality, Artificial intelligence, PARK, Infection, CRISPR, Virus, Technology, Research Triangle Park, Triangle Park (Quezon City), Tencent, Janssen Pharmaceuticals, AMR, Growth, Development, Genetically modified bacteria, CEO, BARDA, GLOBE, Pharmaceutical industry, Antibiotics, Lancet, Locus

RESEARCH TRIANGLE PARK, N.C., May 18, 2022 (GLOBE NEWSWIRE) -- Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases, today announced that it completed a $35 million financing which included a Series B equity financing and conversion of an earlier convertible note. Notable investors participating in the round included Artis Ventures, Tencent Holdings, Viking Global Investors, Johnson and Johnson Innovation – JJDC, Inc. and Discovery Innovations.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., May 18, 2022 (GLOBE NEWSWIRE) -- Locus Biosciences, Inc. (Locus), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases, today announced that it completed a $35 million financing which included a Series B equity financing and conversion of an earlier convertible note.
  • In addition, funds will support the expansion of Locus discovery platform engine and enhancement of its in-house manufacturing capability to support oral solid dose delivery of its products.
  • This financing helps Locus accelerate our growth, while remaining nimble and adaptable.
  • Locus Biosciences is creating a new class of precision biotherapeutics with clinical-stage, engineered bacteriophage treatments for a diverse set of bacterial and microbiome/inflammatory diseases.

Locus Biosciences Secures Financing of up to $25 Million from Hercules Capital

Retrieved on: 
Tuesday, October 19, 2021
Locus Biosciences, Virus, Janssen Pharmaceuticals, List of life sciences, Technology, Biomedical Advanced Research and Development Authority, NYSE, Achievement, Senior, Development, RESEARCH, Research Triangle Park, Infection, BARDA, Artificial intelligence, CEO, PARK, GLOBE, Johnson & Johnson, Bacteria, Learning, Inflammation, Synthetic biology, Hercules, Triangle Park (Quezon City), CRISPR, Pharmaceutical industry, Antibiotics

This agreement with leading biotech lender Hercules underscores the potential of the Locus platform, said Paul Garofolo, Co-founder and CEO of Locus.

Key Points: 
  • This agreement with leading biotech lender Hercules underscores the potential of the Locus platform, said Paul Garofolo, Co-founder and CEO of Locus.
  • It also provides access to valuable growth capital that supports the expansion of our discovery platform engine and in-house manufacturing capacity.
  • Hercules is pleased to enter into this strategic relationship with Locus to support its push to fundamentally change the way bacteria-related diseases are treated.
  • Since inception in 2003, Hercules has committed more than $12 billion to over 530 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing.

Locus Biosciences completes first-of-its-kind controlled clinical trial for CRISPR-enhanced bacteriophage therapy

Retrieved on: 
Wednesday, February 24, 2021
Health sciences, Life sciences, Bacteriophages, Medical specialties, Bacteriophage, Biology, Model organisms, Phage therapy, Escherichia coli, Therapy, Locus Biosciences

These results demonstrate safety and tolerability for LBP-EC01 and help support the overall safety profile for Locus' phage therapy platform.

Key Points: 
  • These results demonstrate safety and tolerability for LBP-EC01 and help support the overall safety profile for Locus' phage therapy platform.
  • The trial met all of its primary and secondary endpoints and demonstrated proof of mechanism, as the worlds first completed, randomized, placebo-controlled trial of recombinant bacteriophage therapy.
  • The results indicate LBP-EC01 exposure can decrease the level of susceptible bacteria in patients infected with E. coli in the bladder.
  • Bacteriophage have been used as antibacterial therapy since shortly after they were discovered in the early 20th century.